Indication
For the treatment of adult and paediatric patients aged 6 and above with facial angiofibroma (facial AF) associated with tuberous sclerosis complex (TSC).
Medicine details
- Medicine name:
- sirolimus (Hyftor)
- SMC ID:
- SMC2710
- Pharmaceutical company
- Plusultra pharma
- BNF chapter
- Skin
- Submission type
- Full
- Publication due date:
- 13 January 2025
- SMC meeting date:
- 03 December 2024
- Patient group submission deadline:
- 01 October 2024